Xevirol

Breast cancer, Kidney cancer, Renal transplant, Liver transplant, Neuroendocrine tumors, Renal cell carcinoma, Astrocytoma, Renal angiomyolipoma,Tuberous sclerosis

May be taken with or without food. Administer consistently with food or consistently without food.

Oral Breast Cancer, Renal Cell Carcinoma, Renal Angiomyolipomas with TSC, Advanced Neuroendocrine Tumors 10 mg once daily with or without food

Patients with hypersensitivity to the active substance, to other rapamycin derivatives, or to any of the excipients. Hypersensitivity reactions manifested by symptoms including, but not limited to, anaphylaxis, dyspnea, flushing, chest pain, or angioedema (e.g., swelling of the airways or tongue, with or without respiratory impairment) have been observed with everolimus and other rapamycin derivatives

Everolimus, a proliferation signal inhibitor, prevents allograft rejection in rodent and nonhuman primate models of allotransplantation. It exerts its immunosuppressive effect by inhibiting the proliferation and thus, clonal expansion, of antigen-activated T cells which is driven by T cell-specific interleukins eg, interleukin-2 and interleukin-15. Everolimus inhibits an intracellular signaling pathway that normally leads to cell proliferation when triggered by the binding of these T cell growth factors to their receptors. The blockage of this signal by everolimus causes cells to be arrested at the G1 stage of the cell cycle. At the molecular level, everolimus forms a complex with the cytoplasmic protein FKBP-12. In the presence of everolimus, the growth factor-stimulated phosphorylation of the p70 S6 kinase is inhibited. Since p70 S6 kinase phosphorylation is under the control of FRAP (also called m-TOR), this finding suggests that the everolimus-FKBP-12 complex binds to and thus, interferes with the function of FRAP. FRAP is a key regulatory protein which governs cell metabolism, growth and proliferation; disabling FRAP function thus explains the cell cycle arrest caused by everolimus.

Patients taking concomitant ACE inhibitor therapy may be at increased risk for angioedema Interstitial lung disease/noninfectious pneumonitis; monitor for clinical symptoms or radiological changes; fatal cases have occurred; manage by dose reduction or discontinuation until symptoms resolve, and consider use of corticosteroids; pulmonary hypertension (including pulmonary arterial hypertension) as a secondary event reported Elicits immunosuppressive effects and may increase risk for infections; some infections have been severe or fatal; monitor for signs and symptoms and treat promptly Pneumocystis jiroveci pneumonia, some with a fatal outcome, reported; this may be associated with concomitant use of corticosteroids or other immunosuppressive agents Mouth ulcers, stomatitis, and oral mucositis are common; management includes mouthwashes (without alcohol or peroxide) and topical treatments May delay wound healing and increase wound-related complications (eg, dehiscence, wound infection, incisional hernia, lymphocele, and seroma) Cases of renal failure (including acute renal failure), some fatal, have been observed May cause angioedema and fluid accumulation Decreases Hgb, lymphocytes, ANC, platelets; increases cholesterol, TG, glucose, creatinine Elevations of serum creatinine, urinary protein, blood glucose, and lipids may occur; decreases in hemoglobin, neutrophils, and platelets may also occur; monitor renal function, blood glucose, lipids, and hematologic parameters prior to treatment and periodically thereafter May impair male fertility Child-Pugh Class C hepatic impairment Avoid use of live vaccines during treatment and close contact with live vaccine recipients Can cause fetal harm when administered to a pregnant woman; advise female patients of reproductive potential to use highly effective contraception while receiving everolimus and for up to 8 weeks after ending treatment. Lactation: distribution into breast milk unknown; not recommended

>10% Stomatitis (44%),Constipation (38%),Infections (37%),Asthenia (33%),Fatigue (31%),Cough (30%),Diarrhea (30%),Rash (29%),Anemia (26%),Nausea (26%),Anorexia (25%),Edema, peripheral (25-45%),Dyspnea (24%),Pyrexia (20%),Vomiting (20%),Headache (19%),Epistaxis (18%),Decreased lymphocytes, Grade 3 (16%),Increased glucose, Grade 3 (15%),Pneumonitis (14%),Pruritus (14%),Dry skin (13%),Decreased Hgb, Grade 3 (12%),Menstrual irregularities (11%) 1-10% (selected) Dysgeusia (10%),Hypertension (4%),Hemorrhage (3%),Tachycardia (3%),CHF (1%)

Pregnancy Based on animal studies and mechanism of action therapy can cause fetal harm when administered to pregnant woman; there are limited case reports of use in pregnant women; however, these reports are not sufficient to inform about risks of birth defects or miscarriage; advise pregnant women of potential risk to fetus Contraception Females Advise female patients of reproductive potential to use effective contraception during treatment and for 8 weeks after last dose Verify the pregnancy status of females of reproductive potential prior to starting treatment Males Based on findings in animal reproduction studies, advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 4 weeks after last dose Infertility Females Menstrual irregularities, secondary amenorrhea, and increases in luteinizing hormone (LH) and follicle stimulating hormone (FSH) occurred in female patients receiving therapy; based on these clinical findings and findings in animals, female fertility may be compromised by treatment with drug Males Based on clinical findings and findings in animals, treatment may impair fertility in male patients; cases of reversible azoospermia reported in male patients receiving therapy; in male rats, sperm motility, sperm count, plasma testosterone levels and fertility were diminished at exposures (AUC) similar to those in patients receiving a dose of 10 mg daily; the fertility index in rats increased when everolimus administration was stopped for a 10-13 week recovery Lactation There are no data on presence of everolimus in human milk, effects on breastfed infant or on milk production; drug and/or its metabolites passed into milk of lactating rats at a concentration 3.5 times higher than in maternal serum; because of potential for serious adverse reactions in breastfed infants from everolimus, advise lactating women not to breastfeed during treatment and for 2 weeks after last dose

CYP3A4 inhibitors &/or inducers, CYP2D6 substrates w/ narrow therapeutic index, PgP inhibitors, rifampicin, ACE inhibitors, grapefruit juice & live vaccines.